Janux Therapeutics, Inc.
JANX Market Cap, Stock Price & Valuation
With a market capitalization (market cap) of $1.02B — a measure of how much the company is worth — Janux Therapeutics, Inc. is the 2575th most valuable company in Healthcare as of July 9, 2026. Shares trade at $16.66, up +3.16% on the day. Over the past year its share price has moved -31.86%.
$16.66
+3.16%gain today
Market position
Market cap rank
#2575
of 2,595
1-day
+3.16%
1-month
+23.32%
6-month
+23.96%
YTD
+22.05%
1-year
-31.86%
5-year
-37.53%
Key figures
Market cap
$1.02B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-7.5
FY 2025
EPS
-$1.83
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
79.71%
FY 2025
Operating margin
-1,576.67%
FY 2025
Net margin
-1,136.25%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$824.95M
FY 2025
EV / EBITDA
-7.39
FY 2025
EV / Sales
82.49
FY 2025
Price / book
0.89
FY 2025
Price / sales
85.51
FY 2025
Earnings yield
-13.29%
FY 2025
FCF yield
-9.74%
FY 2025
Debt / equity
0.02
FY 2025
Current ratio
39.04
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$10M
Gross profit
$7.97M
Operating income
$-157.67M
EBITDA
$-111.6M
Net income
$-113.63M
Diluted EPS
-$1.83
Shares outstanding
61,966,999
Trading
Open
$16.09
Previous close
$16.15
Day range
$15.71 – $16.67
52-week range
$12.12 – $35.34
50-day avg
$14.40
200-day avg
$17.52
Volume
1,364,598
Avg volume
1,106,354
Beta
2.51
Price history
Compare with peers
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Visit websiteCompany info
CEO
David Alan Campbell
IPO date
Jun 11, 2021
Frequently asked questions
How much is Janux Therapeutics, Inc. worth?
As of July 9, 2026, Janux Therapeutics, Inc. (JANX) is worth $1.02B — this is its market capitalization, the total value of all its outstanding shares.
What is Janux Therapeutics, Inc.’s market cap?
Janux Therapeutics, Inc.’s market cap is $1.02B, which ranks it #2575 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
What is Janux Therapeutics, Inc.’s stock price?
Janux Therapeutics, Inc. (JANX) shares trade at $16.66, up 3.16% on the day, as of July 9, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
